Figure 1: Endpoint PCR products for BRCA1 and BRCA2 mutations using positive controls for each mutation. Is clear to see that we have only one amplification product for each one of the mutations. Positive controls are synthetic oligonucleotides with the sequence for each mutation. Lanes: 1, Positive control for wild type (WT) sequence; 2, Positive control for mutated sequence; 3, Negative control where no template was added.